Top Injectable Manufacturer in Cuba – Reliable Pharmaceutical Solutions
- Maulik Sudani
- 3 days ago
- 9 min read
Last Updated: August 23, 2026
TL;DR: Cuba's medicines are regulated by CECMED (Centro para el Control Estatal de Medicamentos, Equipos y Dispositivos Médicos), founded April 21, 1989 under the Ministry of Public Health (MINSAP); CECMED issues the Registro Sanitario required before any medicine can be sold domestically, has held WHO Collaborating Centre status for Health Technology since 2014, and is one of only eight PAHO/WHO-designated National Regulatory Authorities of Regional Reference in the Americas. Unlike most countries in this series, Cuba is not primarily import-dependent: the state holding company BioCubaFarma, formed in 2012, manufactures an estimated 58% of the medicines Cubans consume and supplies more than 900 products to the national health system, while its FARMACUBA subsidiary has historically managed imports of raw materials and finished pharmaceuticals. Cuba has nonetheless experienced a severe, well-documented medicine shortage — by September 2025 an estimated 69% of the country's 651 essential medicines were in short supply and 51% were out of stock — which Cuban authorities and UN/WHO officials attribute largely to hard-currency scarcity and banking difficulties affecting imports; in a major policy shift, reforms effective July 29, 2026 authorized private pharmacies and private import/resale of some medicines for the first time since the 1960s. Cuba has not acceded to the 1961 Hague Apostille Convention, so Certificates of Pharmaceutical Product and GMP certificates from India require full consular/embassy legalization. As the oldest population in Latin America and the Caribbean, Cuba also carries a heavy chronic-disease burden, with cardiovascular disease the leading cause of death and hypertension affecting 37.3% of adults. Farbe Firma, a WHO-GMP certified sterile injectable manufacturer in Gujarat, India producing 100+ injectable products under ISO Class 5 aseptic conditions and exporting to 30+ countries, supports Cuban-bound trade with CTD/ACTD-ready documentation and positions itself as an API/raw-material and CDMO partner for Cuba's domestic industry.
Key Takeaways
CECMED (Centro para el Control Estatal de Medicamentos, Equipos y Dispositivos Médicos) was created on April 21, 1989 under Cuba's Ministry of Public Health (MINSAP) and issues the Registro Sanitario authorizing commercial sale of a medicine, evaluating manufacturing, quality-control, stability and safety/efficacy data alongside the manufacturer's GMP standing. Since 2014, CECMED has held WHO Collaborating Centre status for Health Technology, and PAHO/WHO recognizes it as one of only eight National Regulatory Authorities of Regional Reference in the Americas. We could not confirm a current, published WHO Global Benchmarking Tool maturity level for CECMED and have not stated one here. Farbe Firma structures its own submissions in CTD format to match the categories CECMED's evaluation reviews.
Cuba's pharmaceutical supply is not primarily import-driven the way most countries in this series are: BioCubaFarma, the state biotechnology holding company formed in 2012, manufactures an estimated 58% of the medicines Cubans consume and supplies over 900 products to the national health system, with its FARMACUBA subsidiary historically managing imports of raw materials and finished pharmaceuticals. In a major shift, reforms taking effect July 29, 2026 authorized private pharmacies and, for the first time since the 1960s, private import and resale of some medicines from abroad. How this new channel matures for foreign suppliers is still emerging, but it is a genuine opening alongside the traditional BioCubaFarma/FARMACUBA channel.
Cuba is not a party to the 1961 Hague Apostille Convention, so Certificates of Pharmaceutical Product, GMP certificates and other documents from India require full consular/embassy legalization rather than the faster apostille route available in several other Farbe Firma export markets. Cuba is also the oldest population in Latin America and the Caribbean, with roughly 27% of Cubans over age 60; cardiovascular disease is the leading cause of death, Cuba's 2018-2019 National Health Survey found hypertension in 37.3% of adults, and 2021 health-ministry data recorded registered diabetes prevalence of 66.9 per 1,000 inhabitants, roughly triple the level of 20 years earlier. We could not confirm a current IDF Diabetes Atlas modeled prevalence percentage published specifically for Cuba and have not stated one here.
Cuba's medicine shortage is severe: by September 2025, an estimated 69% of the country's 651 essential medicines were in short supply and 51% were out of stock, and UN and WHO officials reported in 2026 that blackouts and shortages were disrupting emergency care, blood banks, laboratories and immunization programs. Cuban authorities have publicly attributed the shortage chiefly to hard-currency scarcity — citing a need for roughly USD 339 million a year to purchase required medicines — compounded by banking difficulties processing international payments. For Indian manufacturers, the practical takeaway is to plan realistic payment-channel and logistics lead times, and to treat API/raw-material supply and CDMO partnerships as a more realistic near-term opening than a conventional import-registration-tender pipeline.
Introduction: Why an Injectable Manufacturer in Cuba Must Understand a Different Market Structure
Cuba is not a typical case in this series. Most countries Farbe Firma profiles are conventionally import-dependent markets where success hinges on registering with a national regulator and winning institutional tenders. Cuba is different: the state holding company BioCubaFarma manufactures a majority of the medicines Cubans use domestically, and the country has a decades-long track record in vaccine development and biotechnology. What an injectable manufacturer in Cuba actually needs to understand is a market carrying a genuine, well-documented medicine shortage alongside that domestic capability — a shortage Cuban authorities themselves attribute chiefly to hard-currency scarcity and banking-channel friction rather than a lack of manufacturing know-how — plus an aging, chronic-disease burden that keeps injectable demand structurally high.
Farbe Firma Pvt Ltd, operating from Gujarat, India as a WHO-GMP certified sterile injectable manufacturer, produces more than 100 injectable formulations inside ISO Class 5 aseptic filling suites and exports to more than 30 countries under CTD and ACTD dossier formats. Serving Cuba well means preparing documentation CECMED's Registro Sanitario process can evaluate, understanding that BioCubaFarma and its FARMACUBA import arm remain the primary state channel even as 2026 reforms open a private-import pathway, and planning for full consular legalization of Indian certificates since Cuba has not joined the Apostille Convention. Farbe Firma builds its Cuba engagement around all of these realities at once.
What Sets a World-Class Injectable Manufacturer in Cuba Apart
Any credible injectable manufacturer in Cuba has to start from CECMED's Registro Sanitario evaluation, which reviews manufacturing-process documentation, quality-control specifications, stability data and safety/efficacy evidence alongside the applicant's GMP standing; a separate unified Sanitary License for Distribution, Import and Export, introduced under Resolution 79/2023, governs who is authorized to bring medicines into the country. CECMED is a serious regulator by regional standards — it has held WHO Collaborating Centre status since 2014 and is one of only eight PAHO/WHO-designated National Regulatory Authorities of Regional Reference in the Americas — so Farbe Firma treats Cuban dossier preparation with the same rigor as any strongly overseen market, organizing technical files in CTD format.
Beyond registration, an injectable manufacturer in Cuba has to understand who actually buys and imports medicines. BioCubaFarma and its FARMACUBA arm have long been the dominant channel, importing raw materials and finished pharmaceuticals for a domestic industry that itself supplies an estimated 58% of the medicines Cubans consume — a genuine manufacturing capability, not a market without local production. What changed in 2026 is that Cuba's government, responding directly to the shortage crisis, authorized private pharmacies and, for the first time since the 1960s, private import and resale of some medicines from abroad — a development Farbe Firma is tracking closely alongside the traditional state channel.
Quality Systems Behind Every Batch We Ship to Cuba
Every batch leaving Farbe Firma's Gujarat facility passes through the same analytical panel we apply globally, regardless of destination. Identity, assay and related-substance testing run on validated HPLC and GC methods benchmarked against USP, BP, IP and EP monographs, Karl Fischer titration confirms residual moisture in lyophilized and powder-fill products, and every sterile lot undergoes sterility testing and bacterial endotoxin (LAL) testing, alongside sub-visible particulate counts, pH, osmolality and fill-volume verification. This is the certificate-of-analysis and validation documentation CECMED reviewers expect within a Registro Sanitario dossier, and the standard of evidence any BioCubaFarma or FARMACUBA technical evaluation of a prospective API or contract-manufacturing partner would reasonably expect.
Stability data is generated under ICH Q1A(R2) long-term and accelerated conditions, with photostability assessed per ICH Q1B, so shelf-life claims hold up under Cuba's tropical climate and Caribbean shipping realities. Because Cuba has not acceded to the Hague Apostille Convention, our regulatory team builds full consular/embassy legalization lead time into every Cuba-bound document rather than assuming a faster apostille route, and because hard-currency and banking-channel constraints are a documented feature of trading with Cuba today, we structure payment terms and delivery schedules around realistic timelines rather than the faster cycles a conventional tender market might allow.
Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry
Why Farbe Firma is the Trusted Injectable Manufacturer in Cuba for Global Buyers
Cuba's disease burden creates sustained, structural injectable demand that the current shortage crisis has only made more acute. As the oldest population in Latin America and the Caribbean — with close to 27% of Cubans over age 60 — Cuba carries a heavy chronic-disease load: cardiovascular disease is the leading cause of death, the 2018-2019 National Health Survey recorded hypertension in 37.3% of adults, and 2021 health-ministry figures put registered diabetes prevalence at 66.9 per 1,000 inhabitants, roughly triple the level of two decades earlier, with national survey data suggesting a substantial share of cases remain undiagnosed. That combination keeps demand for insulin, cardiovascular and critical-care injectables high even before accounting for the acute shortage — by September 2025, 69% of Cuba's essential medicines were in short supply.
For manufacturers and brand owners, Farbe Firma also functions as a CDMO/CMO partner, offering private-label sterile injectables and API/raw-material supply built on the same WHO-GMP, ISO Class 5 platform, with CTD/ACTD-format technical files ready to support CECMED review. Given that Cuba's own industry has publicly attributed lost production capacity to funding shortfalls, supplier withdrawal and banking difficulties in international payments rather than to a lack of technical capability, an API and contract-manufacturing relationship with BioCubaFarma's network may be a more realistic near-term opening for an Indian manufacturer than assuming a conventional finished-product import-registration-tender pipeline, at least until the 2026 private-import reforms mature.
In practice, succeeding with Cuba means treating CECMED registration, consular legalization lead time and hard-currency/banking realities as one integrated planning problem, not three separate hurdles. Farbe Firma's export team prepares CTD-format dossiers built for CECMED review, factors full embassy legalization into every Cuba-bound quote since no apostille shortcut is available, and structures payment terms around the documented realities of Cuban hard-currency and banking constraints — so whether a partnership develops through BioCubaFarma's traditional channel, a CDMO/API arrangement, or the new private-pharmacy pathway, Cuban counterparts get a realistic plan rather than one built for a market Cuba isn't.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Is Farbe Firma a WHO-GMP certified injectable manufacturer for Cuba?
Yes. Farbe Firma is a WHO-GMP certified sterile injectable manufacturer based in Gujarat, India, operating ISO Class 5 aseptic filling lines and producing more than 100 injectable products for export to over 30 countries. Our documentation is prepared in CTD and ACTD formats to support CECMED's Registro Sanitario review, and we also work as an API/raw-material and CDMO partner for Cuba's domestic pharmaceutical industry.
How does injectable product registration work in Cuba?
CECMED (Centro para el Control Estatal de Medicamentos, Equipos y Dispositivos Médicos), founded in 1989 under the Ministry of Public Health, issues the Registro Sanitario required before any medicine can be sold in Cuba, evaluating manufacturing, quality-control, stability and safety/efficacy data along with the manufacturer's GMP standing. A separate unified Sanitary License, introduced under Resolution 79/2023, governs which entities may import, distribute or export medicines.
Does Cuba manufacture its own medicines, or rely on imports?
Both. BioCubaFarma, Cuba's state biotechnology holding company, manufactures an estimated 58% of the medicines Cubans consume and supplies more than 900 products to the national health system — a genuine domestic capability built over decades. Cuba has also experienced a severe, well-documented medicine shortage in recent years, driven chiefly by hard-currency scarcity and banking-channel difficulties affecting imports of raw materials and finished products, not by an absence of manufacturing capability.
What documentation and payment considerations matter most for Cuba-bound trade?
Because Cuba has not acceded to the 1961 Hague Apostille Convention, Certificates of Pharmaceutical Product and GMP certificates from India require full consular/embassy legalization, which takes longer than an apostille — build that into your timeline. Cuban authorities have also publicly acknowledged hard-currency shortages and banking difficulties processing international payments, so realistic payment-channel and logistics lead times should be built into any Cuba-bound quote from the outset.
Which injectables are in strongest demand in Cuba?
Cuba's aging population — the oldest in Latin America and the Caribbean — and high rates of hypertension (37.3% of adults) and rising diabetes prevalence keep demand for cardiovascular and metabolic injectables, including insulin, structurally high. The ongoing medicine-shortage crisis has also sharpened demand for injectable antibiotics and critical-care formulations, and Farbe Firma's 100+ product range covers all of these categories.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments